Diabetic angiopathy and hemorheological action of troxerutine: An open trial

Abstract

Troxerutine is shown to be of clinical interest in some pathological circumstances particularly in venous insufficiency. One particularly interesting effect of Troxerutine is its hemorheological action. Indeed. it is shown to inhibit the red blood cell hyperaggregation in vitro and in vivo. The aim of the present work is to appreciate the effect of Troxerutine on red blood cell aggregation in diabetic angiopathy. Aggregation measurements were performed with Sefam and Myrenne aggregometers. Moreover, hemodynamic and transcutaneous oxygen pressure measurements were performed. These measurements might help to better understand the clinical effects of Troxerutine.